SAMP reported full year earnings of Rs. 12.7bn (+34% YoY) for CY17, supported mainly by 1) a strong 27% YoY increase in net interest income (driven by robust above-industry loan book growth amid a marginal expansion in NIM); and 2) an improved cost to income ratio which reached the bank’s target of 42% for the year (-5.5ppt YoY) amid a maturing of its branch network (SAMP has a younger branch network vs. peers HNB and COMB, with an average branch age of ~11 years, following an aggressive expansion drive over 2010-2011). Gross NPLs were marginally higher (+3bps to 1.64%) for the year, but remain one of the lowest among the larger private sector banks, thanks to a centralised credit approval system (all loan approvals are carried out by seven zonal offices and the head office which approves all big ticket loans of > Rs. 200mn). The bank reported above-industry loan book growth and deposit growth for the year (+24% YoY respectively).
We conservatively project full year earnings of Rs. 14bn (+11% YoY) for CY18E, given an expected slowdown in credit growth during the year for the bank and the sector as a whole, coupled with a potential sharp hit from increased provisioning due to implementation of SLFRS 9 and a projected tax hit of Rs. 5mn - Rs. 6mn from removal of the notional tax credit on government securities and other tax changes. We expect the company’s cost to income ratio to improve to 40% by end CY18. SAMP’s NIM could be pressured in 1HCY18, in the event of a decline in interest rates, but should improve in 2HCY18. We have not factored in the impact of implementation of the FTL (Financial Transaction Levy) into our projections. At its current price of Rs. 329.80, SAMP trades at an attractive CY18E P/E of 5.1x (based on current share count) and a P/BV of 1.0x (based on current share count & NAVPS as at end December 2017), and continues to offer a strong value proposition to long term investors.
•JKSB is one of 15 founding members of the Colombo Stock Exchange with roots in share trading dating back to 1896, and is a subsidiary of John Keells Holdings PLC (JKH), the largest listed entity on the Colombo Stock Exchange with a market capitalization of US$ 1.3bn.
•JKSB’s core client base is Foreign Institutional Investors, Local Institutions and HNWI’s
•JKSB has a co-branded Research tie up with CIMB and a Research Referral agreement with Credit Suisse, along with trade execution relationships with several other global and regional securities firms.
•JKSB’s trade execution partners include Credit Suisse, CIMB, Merrill Lynch, Exotix, Daiwa, Convergex, Deutsche Asia Securities and Morgan Stanley
•JKSB is a research contributor to Bloomberg on ‘KEEL’
•The JKSB Research Universe covers 72 stocks across 15 sectors, with most Research efforts focused on approximately 45 of the more liquid counters.
•The JKSB Universe constitutes 67% of total market cap and approximately 80% of turnover at the CSE.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.